Evidence map›Paper›PMID 42459191›Full record

ArticleFrontiers in cardiovascular medicine2026

Progression of mitral and tricuspid regurgitation in patients with and without atrial fibrillation.

Michael Koechlin, Rebecca E Paladini, Stefanie Aeschbacher, Christine S Zuern, Ivo Strebel, Michael Coslovsky, Matea Liskij, Ruben Kerler, Philipp Krisai, Leo H Bonati and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Michael KoechlinDepartment of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Rebecca E PaladiniDepartment of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Stefanie AeschbacherDepartment of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Christine S ZuernDepartment of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Ivo StrebelDepartment of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Michael CoslovskyDepartment of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Matea LiskijDepartment of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Ruben KerlerDepartment of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Philipp KrisaiDepartment of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Leo H BonatiRheinfelden Rehabilitation Clinic, Rheinfelden, Switzerland.
David ConenPopulation Health Research Institute, Hamilton, ON, Canada.
Felix MahfoudDepartment of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Stefan OsswaldDepartment of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Michael KühneDepartment of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Beat A KaufmannDepartment of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Mitral (MR) and tricuspid regurgitation (TR) are common valvular disorders that may progress over time. Atrial fibrillation (AF) affects atrial structure and may contribute to the progression of MR or TR. However, longitudinal data quantifying progression rates are limited. We aimed to assess MR and TR progression in patients with and without AF. Methods: A total of 412 patients with and without AF from the Swiss-AF and BEAT-AF cohorts between 2010 and 2023 were studied. MR and TR severity were graded using the first and last available transthoracic echocardiogram (TTE). The primary endpoint was any progression. Clinically relevant progression additionally required at least moderate severity on the second TTE. Multivariable logistic regression analyses were performed to examine the association between AF and progression of MR or TR. Results: Median age at first TTE was 74 years (IQR: 69-81, 26% female). Incidence rates of any MR progression were 7.3 vs. 15.0 and of clinically relevant progression 3.3 vs. 3.9 per 100 person-years in AF vs. non-AF patients. For TR, incidence rates were 9.9 vs. 8.9 and 5.2 vs. 2.1 per 100 person-years, respectively. In multivariable analyses, AF was independently associated with both a higher likelihood of any TR progression and clinically relevant TR progression, but not with MR progression. Conclusion: AF was associated with higher rates of progression of TR severity, including clinically relevant progression. However, AF was not associated with higher rates of progression of MR.

Indexed as

atrial fibrillationatrioventricular regurgitationmitral regurgitationtricuspid regurgitationvalvular disease

Identifiers

PMID42459191
PMCPMC13369044

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.